- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Efficacy of perampanel in paroxysmal kinesigenic dyskinesia () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1348;
Current studies suggest that the pathophysiology of PKD is highly related with the glutamate receptor. Our study shows that perampanel is effective in PKD treatment, especially reducing the frequency of attacks.
- |||||||||| levetiracetam / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Paroxysmal Kinesigenic Dyskinesia caused by a novel missense variant in NBEA () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_827;
Levetiracetam was tried up to 2000 mg twice daily, which lead to mild reduction of attacks... This case highlights that should be considered in cases of negative PKD and can be treated with oxcarbazepine.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., oxcarbazepine / Generic mfg.
Colon Cancer: An Unexpected Cause of Dysphagia (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3551;
Oxcarbazepine, levetiracetam, topiramate did not affect bone metabolism, and lamotrigine corrected some of the abnormal markers of bone metabolism in epileptic patients. At time of presentation, the patient
- |||||||||| Journal: A 5-Year Study of Antiseizure Medications (ASMs) Monitoring in Patients with Neuropsychiatric Disorders in an Italian Clinical Center. (Pubmed Central) - Jul 29, 2023
The most used ASMs were Valproate (VPA: 54.5%) and Levetiracetam (LEV: 18.6%), followed by Oxcarbazepine (OxCBZ: 8.3%) and Carbamazepine (CBZ: 7.2%), whereas the associations LEV/VPA, Ethosuximide (ESM)/VPA, and CBZ/VPA were the most frequently proposed...For VPA, there was a decrease of mean C(p) across ages, from adolescents to older patients, while the C(p) of LEV, CBZ, OxCBZ, and Topiramate (TPM) showed a slight tendency to increase...Finally, the ASMs subjected to multiple dosing starting from an initial subtherapeutic C(p) increased their level at different time points within a year, reaching the reference range for some of them. In conclusion, the present study suggests that TDM is widely applied to monitor ASMs C(p), finding many of them within the reference range, as a demonstration of its utility in clinical practice.
- |||||||||| carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Age-Related Changes in Epilepsy Characteristics and Response to Antiepileptic Treatment in Autism Spectrum Disorders. (Pubmed Central) - Jul 29, 2023
Interestingly, atypical Landau-Kleffner syndrome was associated with mitochondrial dysfunction and NDR, suggesting a novel syndrome. These interesting findings need to be verified in independent, prospectively collected cohorts, but nonetheless, these data provide insights into novel relationships that may assist in a better understanding of epilepsy in ASD and provide insight into personalizing epilepsy care in ASD.
- |||||||||| oxcarbazepine / Generic mfg.
PK/PD data, Journal: Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. (Pubmed Central) - Jul 26, 2023
These interesting findings need to be verified in independent, prospectively collected cohorts, but nonetheless, these data provide insights into novel relationships that may assist in a better understanding of epilepsy in ASD and provide insight into personalizing epilepsy care in ASD. What is New:
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Review, Journal: The evidence for repurposing anti-epileptic drugs to target cancer. (Pubmed Central) - Jul 7, 2023
Valproic acid, oxcarbazepine, lacosamide, lamotrigine, and levetiracetam are the drugs that showed potential beneficial outcomes against different cancers. Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Ospolot (sultiam) / AOP Orphan Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika
Enrollment open, Trial completion date, Trial primary completion date: EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov) - Jul 3, 2023
P=N/A, N=1000, Recruiting,
Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials. Unknown status --> Recruiting | Trial completion date: Jun 2022 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Jun 2026
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: Antiseizure Medication-Induced Alopecia: A Literature Review. (Pubmed Central) - Jun 27, 2023
Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Journal: Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. (Pubmed Central) - Jun 14, 2023
Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam. This study provides reassuring evidence that lamotrigine, carbamazepine, and oxcarbazepine are not associated with long-term behavioral or developmental disorders but cannot rule out risks with higher doses.
- |||||||||| sodium valproate / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Journal, Monotherapy: Change in Apo B100/A1 Ratio in Children With Epilepsy on Monotherapy With Sodium Valproate, Oxcarbazepine or Levetiracetam. (Pubmed Central) - Jun 13, 2023
A prospective longitudinal study was conducted to assess the Apo B100/A1 ratio as a marker of cardiovascular risk in children with epilepsy aged 5-14 years on long-term anti-seizure medication monotherapy with either sodium valproate, oxcarbazepine, or levetiracetam. Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05).
- |||||||||| FASTKD2 gene mutation presenting with status epilepticus evolving to super-refractory status in dizygotic twins (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_749;
Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05). Mitochondrial status epilepticus is reported rarely and challenging in terms of management and prognosis.Other than a lateralization difference, this dizygotic twins had identical clinical and radiological findings which further expands the phenotype of FASTKD2 gene mutation.
- |||||||||| oxcarbazepine / Generic mfg.
BIALLELIC PI4KA MUTATION: A WIDE SPECTRUM OF SYNDROMES (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_679;
Most importantly, we describe a third phenotype previously only reported in three fetuses who showed bilateral polymicrogyria with cerebellar hypoplasia and joint contractures. The phenotypes presented by these fetuses may represent the most severe extreme of the spectrum.
- |||||||||| Report of life threatening ictal apnoeas responsive to Ketogenic Diet (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_511;
Ketogenic diet was effective in this patient and despite she does not remain seizure free, the features of the seizures have changed being now safe for the patient being out of hospital. The ketogenic diet should be considered earlier as treatment in patients with these type of seizures.
- |||||||||| oxcarbazepine / Generic mfg.
Journal: The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells. (Pubmed Central) - May 20, 2023
Furthermore, the treated GSC spheroids were 82% smaller (mean volume 1.6 nL vs. 8.7 nL; p = 0.01 (live/dead fluorescence staining)), and the apoptotic events increased by more than 50% (caspase-3/7 activity; p = 0.006). Taken together, this drug screen of a large series of antiepileptic drugs identified oxcarbazepine as a potent proapoptotic drug in IDH GSCs, which combines antiepileptic and antineoplastic properties to treat this seizure-prone patient population.
- |||||||||| A Rare Case of Cannabis Withdrawal Precipitating First Manic Episode (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_732;
The patient was initially treated with the combination of Depakote, Abilify, and Cogentin, with his symptoms improving over the course of two weeks. However, the patient developed new onset visual hallucinations, delirium, and blurred vision, which led to the discontinuation of these medications, and the initiation of Oxcarbazepine and Risperidone, on which the patient
- |||||||||| Asymptomatic Creatine Kinase Level of 183,645 U/L in a Patient With Symptomatic Bipolar Disorder: A Case Report (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_497;
In the ED, he received oral olanzapine 30 mg, intramuscular haloperidol 7 mg, and oral ziprasidone 30 mg for agitation...He was eventually medically cleared and transferred to the psychiatric unit where varying doses of olanzapine and sodium valproate were trialed...He ultimately stabilized on oxcarbazepine 600 mg twice daily and aripiprazole 20 mg daily with a CK level of 817 U/L...His psychiatric treatment options were limited due to elevated CK levels. Psychiatric patients with asymptomatic CK elevation should undergo a thorough evaluation with cautious but continued consideration of neuroleptic use.
- |||||||||| carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Biomarker, Journal: Typewriter Tinnitus: Value of ABR as a Diagnostic and Prognostic Indicator. (Pubmed Central) - May 12, 2023
Patients with IPL I-III greater than 2.4?ms, older age and poorer hearing are more likely to relapse. In addition to the neurovascular conflict of the cochleovestibular nerve, the etiologies of neuroinflammation and demyelinating diseases are also possible for typewriter tinnitus.
- |||||||||| oxcarbazepine / Generic mfg.
Therapeutic potential of Oxcarbazepine in Central Diabetes Insipidus (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_2038;
In addition to the neurovascular conflict of the cochleovestibular nerve, the etiologies of neuroinflammation and demyelinating diseases are also possible for typewriter tinnitus. Abstract is embargoed at this time.
- |||||||||| BIUXX (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_513;
Use of Spironolactone unmasked natriuresis by blocking aldosterone activity on the intercalated cells of the renal nephron. Stopping Oxcarbazepine ultimately resulted in hyponatremia resolution.
- |||||||||| oxcarbazepine / Generic mfg.
Journal: Functional analysis of a novel de novo SCN2A variant in a patient with seizures refractory to oxcarbazepine. (Pubmed Central) - May 8, 2023
We showed the importance of functional analysis for a SCN2A variant with unknown significance to determine pathogenicity, drug reactions, and genotype-phenotype correlations. For patients suffering from early infantile epilepsies, the use of oxcarbazepine in some SCN2A-related epilepsies requires vigilance to assess the possibility of epilepsy worsening.
- |||||||||| gabapentin / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion date, Trial primary completion date: Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study (clinicaltrials.gov) - Apr 26, 2023
P3, N=60, Not yet recruiting,
For patients suffering from early infantile epilepsies, the use of oxcarbazepine in some SCN2A-related epilepsies requires vigilance to assess the possibility of epilepsy worsening. Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| oxcarbazepine / Generic mfg.
Biomarker, Review, Journal: Pharmacogenomics of oxcarbazepine in the treatment of epilepsy. (Pubmed Central) - Apr 24, 2023
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 The authors collected all the information on the clinically reported associations between
- |||||||||| Journal: NICOTINIC ACETYLCHOLINE RECEPTORS AND EPILEPSY. (Pubmed Central) - Mar 14, 2023
Understanding the balance of the epileptogenic effects in adult and developing networks is essential to plan rational therapy at different ages. Combining this knowledge with a deeper understanding of the functional and pharmacological properties of individual mutations will advance precision and personalized medicine approaches in nAChR-dependent epilepsy.
|
